首页> 外文期刊>Clinical proteomics. >Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms
【24h】

Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms

机译:导管内乳头状黏液性肿瘤中与恶性肿瘤相关的胰腺囊液蛋白定量蛋白质组学分析

获取原文

摘要

The application of advanced imaging technologies for identifying pancreatic cysts has become widespread. However, accurately differentiating between low-grade dysplasia (LGD), high-grade dysplasia (HGD), and invasive intraductal papillary mucinous neoplasms (IPMNs) remains a diagnostic challenge with current biomarkers, necessitating the development of novel biomarkers that can distinguish IPMN malignancy. Cyst fluid samples were collected from nine IPMN patients (3 LGD, 3 HGD, and 3 invasive IPMN) during their pancreatectomies. An integrated proteomics approach that combines filter-aided sample preparation, stage tip-based high-pH fractionation, and high-resolution MS was applied to acquire in-depth proteomic data of pancreatic cyst fluid and discover marker candidates for IPMN malignancy. Biological processes of differentially expressed proteins that are related to pancreatic cysts and aggressive malignancy were analyzed using bioinformatics tools such as gene ontology analysis and Ingenuity pathway analysis. In order to confirm the validity of the marker candidates, 19 cyst fluid samples were analyzed by western blot. A dataset of 2992 proteins was constructed from pancreatic cyst fluid samples. A subsequent analysis found 2963 identified proteins in individual samples, 2837 of which were quantifiable. Differentially expressed proteins between histological grades of IPMN were associated with pancreatic diseases and malignancy according to ingenuity pathway analysis. Eighteen biomarker candidates that were differentially expressed across IPMN histological grades were discovered—7 DEPs that were upregulated and 11 that were downregulated in more malignant grades. HOOK1 and PTPN6 were validated by western blot in an independent cohort, the results of which were consistent with our proteomic data. This study demonstrates that novel biomarker candidates for IPMN malignancy can be discovered through proteomic analysis of pancreatic cyst fluid.
机译:先进的成像技术在识别胰腺囊肿中的应用已经广泛普及。然而,准确区分低度发育异常(LGD),高度发育异常(HGD)和浸润性导管内乳头状黏液性肿瘤(IPMN)仍然是当前生物标记物的诊断挑战,因此有必要开发能够区分IPMN恶性肿瘤的新型生物标记物。在他们的胰腺切除术期间,从九名IPMN患者(3例LGD,3例HGD和3例侵入性IPMN)中收集了囊肿液样本。结合了过滤器辅助样品制备,基于阶段提示的高pH分离和高分辨率MS的集成蛋白质组学方法,用于获取胰腺囊肿液的深入蛋白质组学数据并发现IPMN恶性肿瘤的候选标记物。使用生物信息学工具,例如基因本体分析和独创性途径分析,分析了与胰腺囊肿和侵袭性恶性肿瘤相关的差异表达蛋白的生物学过程。为了证实候选标记物的有效性,通过蛋白质印迹分析了19个囊液样品。从胰腺囊肿液样本构建了2992个蛋白质的数据集。随后的分析发现,在单个样品中鉴定出2963种蛋白质,其中2837种是可定量的。根据独创性途径分析,IPMN组织学等级之间差异表达的蛋白与胰腺疾病和恶性肿瘤相关。发现了18个在IPMN组织学等级之间差异表达的生物标志物候选物-7个DEP上调,而11个DEP在更恶性等级中下调。 HOOK1和PTPN6在独立的队列中通过Western blot验证,其结果与我们的蛋白质组学数据一致。这项研究表明,可以通过蛋白质组学分析胰腺囊肿液发现IPMN恶性肿瘤的新型生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号